<DOC>
	<DOCNO>NCT00245427</DOCNO>
	<brief_summary>A study report outcomes patient fail respond beta-lactam macrolide antibiotic community</brief_summary>
	<brief_title>Outcomes Patients Not Responding Antibiotics Community</brief_title>
	<detailed_description>To document describe clinical , microbiological , pharmacoeconomic outcome two hundred patient fail respond outpatient macrolide beta-lactam therapy . Evaluable patient must positive culture obtain fail initial macrolide beta-lactam . The isolated pathogen must know MIC antibiotic class fail respond ( i.e . macrolide b-lactam ) . The isolate must available sent central laboratory MIC testing</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Sinusitis</mesh_term>
	<mesh_term>Pneumonia , Bacterial</mesh_term>
	<mesh_term>Bronchitis , Chronic</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>beta-Lactams</mesh_term>
	<mesh_term>Lactams</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<criteria>Patients fail respond least three ( ABECB CAP ) five ( AMS/ABRS/AECRS ) day macrolide blactam therapy meeting protocol criterion acute bacterial exacerbation chronic bronchitis ( ABECB ) , community acquire pneumonia ( CAP ) acute maxillary sinusitis ( AMS ) eligible enrollment . All patient , whether enrol retrospectively concurrently , must positive culture . The pathogenic bacteria must identify local laboratory know susceptibility antibiotic class patient fail respond ( i.e . macrolide blactam ) . The isolate must send Study Coordinating Center precise MIC determination . Patients present follow include study : 1 . Life expectancy &lt; 3 month underlie disease 2 . Underlying lung carcinoma 3 . Cystic fibrosis</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>beta-lactam</keyword>
	<keyword>macrolide</keyword>
	<keyword>antibiotic</keyword>
</DOC>